Instrucciones de búsqueda:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Navegar por los elementos (717 total)
-
Autor: Vikramjit Mukherjee, Lauren M Sauer, Aneesh K Mehta, Sophia Y Shea, Paul D Biddinger, Brendan G Carr, Laura E Evans, Shelly Schwedhelm, John J Lowe, John J Lowe
Tema: Emergency Management
Tipo de elemento: Publicación
Fecha de actualización: 2022-05-31
Descripción: Infectious disease outbreaks and pandemics have repeatedly threatened public health and have severely strained healthcare delivery systems throughout the past century. Pathogens causing respiratory illness, such as influenza viruses and… -
Autor: Jonathan D Grein, Jennifer A Garland, Christa Arguinchona, Maria G Frank, Brian T Garibaldi, Amanda Grindle, Angela Hewlett, Susan Kline, Corri B Levine, Aneesh Mehta, Vikramjit Mukherjee, Lauren M Sauer, Eileen F Searle, Sharon Vanairsdale, Angela…
Tema: Emergency Management
Tipo de elemento: Publicación
Fecha de actualización: 2022-05-31
Descripción: The National Emerging Special Pathogens Training and Education Center (NETEC) was established in 2015 to improve the capabilities of healthcare facilities to provide safe and effective care to patients with Ebola and other special pathogens in the… -
Autor: ACTT- Study Group
Tema: Treatment & Care
Tipo de elemento: Publicación
Fecha de actualización: 2022-05-23
Descripción: Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to… -
Autor: Science Working Group of the National Emerging Special Pathogens Training and Education Center (NETEC) Special Pathogens Research Network (SPRN)
Tema: General
Tipo de elemento: Publicación
Fecha de actualización: 2022-04-05
Descripción: This summary on Lassa virus (LASV) infection and Lassa fever disease (LF) was developed from a clinical perspective to provide clinicians with a condensed, accessible understanding of the current literature. The information provided highlights… -
Autor: Jocelyn J Herstein, Paul D Biddinger, Shawn G Gibbs, Angela L Hewlett, Aurora B Le, Michelle M Schwedhelm, John J Lowe
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2022-02-22
Descripción: In response to the 2014-2016 West Africa Ebola virus disease (EVD) epidemic, the Centers for Disease Control and Prevention (CDC) designated 56 US hospitals as Ebola treatment centers (ETCs) with high-level isolation capabilities. We aimed to… -
Autor: Herminia Machry, Zorana Matić, Yeinn Oh, Jennifer R DuBose, Jill S Morgan, Kari L Love, Jesse T Jacob, Craig M Zimring
Tema: Infection Control
Tipo de elemento: Publicación
Fecha de actualización: 2022-02-14
Descripción: Understand how the built environment can affect safety and efficiency outcomes during doffing of personal protective equipment (PPE) in the context of coronavirus disease 2019 (COVID-19) patient care.Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
-
Autor: Bar-On, Yinon M., Yair Goldberg, Micha Mandel, Omri Bodenheimer, Laurence Freedman, Nir Kalkstein, Barak Mizrahi, Sharon Alroy-Preis, Nachman Ash, Ron Milo, and Amit Huppert.
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-10-07
Descripción: On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at least 5… -
Autor: the BLAZE-1 Investigators
Tema: Treatment & Care
Tipo de elemento: Publicación
Fecha de actualización: 2021-10-07
Descripción: Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and… -
Autor: Li, L., L. B. Robinson, R. Patel, A. B. Landman, X. Fu, E. S. Shenoy, D. M. Hashimoto, A. Banerji, P. G. Wickner, U. Samarakoon, C. M. Mancini, Y. Zhang, and K. G. Blumenthal.
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-10-01
Descripción: Allergic history in individuals with confirmed anaphylaxis to a messenger RNA (mRNA) COVID-19 vaccine is common. However, the risk factors for allergy symptoms after receiving the vaccine are unknown.